EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A Plasma-based Deep Proteomic Platform for early-stage Breast Cancer Detection

Alec Horrmann, Yash Travadi, Kevin Mallery, Grant Schaap, Kaylee Judith Kamalanathan, Nathaniel R Bristow, Catalina Galeano-Garces, Song Yi Bae, Harrison Ball, Alexa R Hesch, Sarah Pederson, Badrinath R Konety und 2 weitere

Endocrinology · 2026

DOI: 10.1210/endocr/bqaf180 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2026. Verfasst von Alec Horrmann und 13 weiteren Autor:innen. Beteiligte Einrichtung: Astrin Biosciences, Saint Paul, MN 55114, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Proteomics, Early Detection of Cancer, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the widespread use of mammography as the standard of care for breast cancer screening, its accuracy remains limited for select patient populations, such as women with high breast density. Liquid biopsy-based tests offer an accessible complement to conventional screening methods. Here, we conducted a case-control study to develop a plasma-based protein classifier to distinguish between those with early-stage breast cancer and healthy individuals. A total of 335 women, comprising 116 patients with newly diagnosed, treatment-naïve breast cancer (stage 0-2) and 219 healthy controls, had plasma samples collected and processed in a blinded manner using a sample preparation method coupled with semiquantitative, label-free mass spectrometry-based analysis. The median number of proteins detected per patient across breast cancer and healthy individuals was 6991 and 6818, respectively. A machine learning-based classifier was trained and validated on patient proteome profiles using a leave-one-out cross-validation approach to identify patients with breast cancer. The classifier achieved an area under the curve of 0.96 (95% CI, 0.93-0.97), with a sensitivity of 86.2% (95% CI, 78.8-91.3%) and a specificity of 90.4% (95% CI, 85.8-93.6%). In patients with breast cancer, the classifier retained >85% sensitivity regardless of breast density (low density: 87.2%, high density: 90.2%) at 90% specificity. Our workflow demonstrates the potential of plasma proteomics as a potent diagnostic tool in early-stage breast cancer screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsProteomicsEarly Detection of CancerBiomarkers, TumorHumansFemaleMiddle AgedCase-Control StudiesAdultAgedNeoplasm StagingSensitivity and Specificity

Stichwörter der Autor:innen

breast cancerdeep proteomicsearly detectionliquid biopsymachine learningmass spectrometry

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Astrin Biosciences, Saint Paul, MN 55114, USA.
  • Allina Health, Minneapolis, MN 55407, USA.

ORCID-Profile: Justin M Drake

Zitieren

APA

Horrmann, A., Travadi, Y., Mallery, K., Schaap, G., Kamalanathan, K. J., Bristow, N. R., Galeano-Garces, C., Bae, S. Y., Ball, H., Hesch, A. R., Pederson, S., Konety, B. R., Olimpiadi, Y., & Drake, J. M. (2026). A Plasma-based Deep Proteomic Platform for early-stage Breast Cancer Detection. Endocrinology. https://doi.org/10.1210/endocr/bqaf180

Vancouver

Horrmann A, Travadi Y, Mallery K, Schaap G, Kamalanathan KJ, Bristow NR, et al. A Plasma-based Deep Proteomic Platform for early-stage Breast Cancer Detection. Endocrinology. 2026. doi:10.1210/endocr/bqaf180

BibTeX
@article{Horrmann2026,
  author = {Horrmann, Alec and Travadi, Yash and Mallery, Kevin and Schaap, Grant and Kamalanathan, Kaylee Judith and Bristow, Nathaniel R and Galeano-Garces, Catalina and Bae, Song Yi and Ball, Harrison and Hesch, Alexa R and Pederson, Sarah and Konety, Badrinath R and Olimpiadi, Yuliya and Drake, Justin M},
  title = {A Plasma-based Deep Proteomic Platform for early-stage Breast Cancer Detection},
  journal = {Endocrinology},
  year = {2026},
  doi = {10.1210/endocr/bqaf180}
}
Kostenlos starten →